RT Book, Section
A1 Cantilena, Louis R.
A2 Nelson, Lewis S.
A2 Howland, Mary Ann
A2 Lewin, Neal A.
A2 Smith, Silas W.
A2 Goldfrank, Lewis R.
A2 Hoffman, Robert S.
SR Print(0)
ID 1163021830
T1 Drug Development, Adverse Drug Events, and Postmarketing Surveillance
T2 Goldfrank's Toxicologic Emergencies, 11e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9781259859618
LK accesspharmacy.mhmedical.com/content.aspx?aid=1163021830
RD 2024/04/19
AB This  chapter  will  focus  on  drug-induced  diseases  that  occur  as  expected  or  unexpected  adverse  drug  events  (ADEs),  as  a  drug–drug  interaction  or  an  ADE  causing  an  untoward  drug–disease  interaction.  Also  included  in  this  chapter  is  a  brief  overview  of  the  drug  development  process  in  the  United  States  and  specific  aspects  of  the  process  that  relate  to  the  development  of  antidotes.  In  addition,  a  discussion  of  an  approach  to  the  diagnosis  of  drug-induced  disease,  monitoring  of  drug  safety  postapproval,  and  the  suggested  role  for  the  clinical  and  medical  toxicologists  in  the  discovery,  reporting,  and  prevention  of  ADEs.